JP2024540220A5 - - Google Patents
Info
- Publication number
- JP2024540220A5 JP2024540220A5 JP2024525855A JP2024525855A JP2024540220A5 JP 2024540220 A5 JP2024540220 A5 JP 2024540220A5 JP 2024525855 A JP2024525855 A JP 2024525855A JP 2024525855 A JP2024525855 A JP 2024525855A JP 2024540220 A5 JP2024540220 A5 JP 2024540220A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- fusion polypeptide
- dsg2
- pharmaceutical composition
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163274707P | 2021-11-02 | 2021-11-02 | |
| US63/274,707 | 2021-11-02 | ||
| PCT/US2022/079106 WO2023081674A1 (en) | 2021-11-02 | 2022-11-02 | Dsg2 compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540220A JP2024540220A (ja) | 2024-10-31 |
| JP2024540220A5 true JP2024540220A5 (https=) | 2025-11-11 |
Family
ID=84569745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525855A Pending JP2024540220A (ja) | 2021-11-02 | 2022-11-02 | Ｄｓｇ２組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240279304A1 (https=) |
| EP (1) | EP4426430A1 (https=) |
| JP (1) | JP2024540220A (https=) |
| KR (1) | KR20240110819A (https=) |
| CN (1) | CN118369351A (https=) |
| AR (1) | AR127555A1 (https=) |
| AU (1) | AU2022382972A1 (https=) |
| CA (1) | CA3236070A1 (https=) |
| IL (1) | IL312219A (https=) |
| MX (1) | MX2024005327A (https=) |
| TW (1) | TW202334190A (https=) |
| WO (1) | WO2023081674A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965197A (en) | 1987-06-12 | 1990-10-23 | Massachusetts Institute Of Technology | Coryneform expression and secretion system |
| KR100316347B1 (ko) | 1998-09-15 | 2002-08-27 | 한미약품(주) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 |
| DE10057397A1 (de) | 2000-11-18 | 2002-05-23 | Hella Kg Hueck & Co | Vorrichtung zur Ölstandsmessung |
| US8093016B2 (en) | 2007-05-21 | 2012-01-10 | Danisco Us Inc. | Use of an aspartic protease (NS24) signal sequence for heterologous protein expression |
| US8324578B2 (en) | 2008-09-30 | 2012-12-04 | Apple Inc. | Hidden sensors in an electronic device |
| US8975041B2 (en) | 2009-09-10 | 2015-03-10 | Biocon Limited | Fusion proteins and method of expression thereof |
| JP2012107935A (ja) * | 2010-11-16 | 2012-06-07 | Mitsubishi Chemicals Corp | Ｄｅｓｍｏｇｌｅｉｎ−２蛋白質による脳梗塞の検査方法 |
| CN103648489A (zh) | 2011-05-11 | 2014-03-19 | 儿童医疗中心有限公司 | 多抗原提呈免疫原性组合物及其方法和用途 |
| US20190353652A1 (en) * | 2017-01-13 | 2019-11-21 | The Hospital For Sick Children | Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy |
| WO2022132854A1 (en) * | 2020-12-15 | 2022-06-23 | Arvada Therapeutics, Inc. | Dsg2 compositions and methods for the treatment of covid-19 |
-
2022
- 2022-11-02 MX MX2024005327A patent/MX2024005327A/es unknown
- 2022-11-02 CA CA3236070A patent/CA3236070A1/en active Pending
- 2022-11-02 KR KR1020247018502A patent/KR20240110819A/ko active Pending
- 2022-11-02 IL IL312219A patent/IL312219A/en unknown
- 2022-11-02 WO PCT/US2022/079106 patent/WO2023081674A1/en not_active Ceased
- 2022-11-02 AR ARP220103004A patent/AR127555A1/es unknown
- 2022-11-02 EP EP22829631.5A patent/EP4426430A1/en active Pending
- 2022-11-02 AU AU2022382972A patent/AU2022382972A1/en active Pending
- 2022-11-02 CN CN202280073102.9A patent/CN118369351A/zh active Pending
- 2022-11-02 JP JP2024525855A patent/JP2024540220A/ja active Pending
- 2022-11-02 TW TW111141818A patent/TW202334190A/zh unknown
-
2024
- 2024-05-01 US US18/652,115 patent/US20240279304A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12152060B2 (en) | Interleukin-2 variants and methods of uses thereof | |
| TWI856979B (zh) | 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法 | |
| Ko et al. | An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies | |
| US9518132B2 (en) | Protein complexes for antigen binding and methods of use | |
| JP6850255B2 (ja) | 抗−ｃｄ４７抗体及びその使用 | |
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP2009523459A5 (https=) | ||
| BR112019016104A2 (pt) | composição farmacêutica de baixo ph compreendendo construtos de anticorpo que empregam células t | |
| CN107001468A (zh) | Cd3结合结构域 | |
| JP2018504092A5 (https=) | ||
| JP2023532129A5 (https=) | ||
| JP2022549172A5 (https=) | ||
| JPWO2017110980A1 (ja) | 増強された活性を有する抗体及びその改変方法 | |
| CA3134224A1 (en) | Composition for preventing or treating brain and nervous system disease | |
| TWI801336B (zh) | 重組靜脈內免疫球蛋白（ｒＩＶＩＧ）組合物及其生產方法和應用 | |
| JP2022540918A5 (https=) | ||
| JP2024504777A5 (https=) | ||
| JP2024504923A5 (https=) | ||
| JP2021518132A5 (https=) | ||
| US20230293648A1 (en) | Stabilized ace2 variant, ace2-fc fusion protein using same, and method for preventing or treating covid-19 | |
| JP2024500250A5 (https=) | ||
| JP2023551668A5 (https=) | ||
| JP2024540220A5 (https=) | ||
| JP2024544531A (ja) | 位置４２９に変異を有するｆｃ領域成分を含む免疫療法タンパク質 | |
| US20240376229A1 (en) | Interferon receptor antagonists and uses thereof |